2022
Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)
Bassir Nia A, Orejarena MJ, Flynn L, Luddy C, D’Souza D, Skosnik PD, Pittman B, Ranganathan M. Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC). Psychopharmacology 2022, 239: 1621-1628. PMID: 35438304, PMCID: PMC11215802, DOI: 10.1007/s00213-022-06135-3.Peer-Reviewed Original ResearchConceptsRey Auditory Verbal Learning TaskPsychotomimetic States InventoryCognitive effectsAuditory Verbal Learning TaskSubjective effectsDelta-9-TetrahydrocannabinolSex differencesVerbal learning taskDissociative Symptoms ScaleFemale participantsMain psychoactive constituentSignificant main effectPerceptual alterationsLearning taskStates InventoryPsychoactive constituentSignificant sex differencesMain effectMale participantsVisual analog scaleSymptom ScaleTest dayEffects of cannabinoidsParticipantsPsychotomimetic effects
2019
The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population. The Journal Of Clinical Psychiatry 2019, 80 PMID: 31265768, PMCID: PMC8445109, DOI: 10.4088/jcp.18m12539.Peer-Reviewed Original ResearchConceptsToxicology screenRelevance of sexSynthetic cannabinoid useSC usePositive urine toxicology screenCannabinoid useUrine toxicology screenRetrospective chart reviewPositive toxicology screenEffects of cannabinoidsSC usersRates of psychosisChart reviewPharmacologic treatmentClinical symptomsInpatient populationInpatient settingPsychotic presentationsUse of substancesStudy groupHigh riskPsychiatric unitCurrent evidenceControl groupPsychosis